BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 23913718)

  • 1. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
    Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
    Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
    Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
    Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
    Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab for patients with advanced mucosal melanoma.
    Postow MA; Luke JJ; Bluth MJ; Ramaiya N; Panageas KS; Lawrence DP; Ibrahim N; Flaherty KT; Sullivan RJ; Ott PA; Callahan MK; Harding JJ; D'Angelo SP; Dickson MA; Schwartz GK; Chapman PB; Gnjatic S; Wolchok JD; Hodi FS; Carvajal RD
    Oncologist; 2013 Jun; 18(6):726-32. PubMed ID: 23716015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
    Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD
    Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab plus ipilimumab in advanced melanoma.
    Wolchok JD; Kluger H; Callahan MK; Postow MA; Rizvi NA; Lesokhin AM; Segal NH; Ariyan CE; Gordon RA; Reed K; Burke MM; Caldwell A; Kronenberg SA; Agunwamba BU; Zhang X; Lowy I; Inzunza HD; Feely W; Horak CE; Hong Q; Korman AJ; Wigginton JM; Gupta A; Sznol M
    N Engl J Med; 2013 Jul; 369(2):122-33. PubMed ID: 23724867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
    PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
    Heppt MV; Amaral T; Kähler KC; Heinzerling L; Hassel JC; Meissner M; Kreuzberg N; Loquai C; Reinhardt L; Utikal J; Dabrowski E; Gesierich A; Pföhler C; Terheyden P; Thoms KM; Zimmer L; Eigentler TK; Kirchberger MC; Stege HM; Meier F; Schlaak M; Berking C
    J Immunother Cancer; 2019 Nov; 7(1):299. PubMed ID: 31722735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender C; Enk A; Gutzmer R; Hassel JC
    Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
    Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
    Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
    Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
    Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
    Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
    J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.